Total-Body Parametric 18F-FDG PET of COVID-19
Not Applicable
Completed
- Conditions
- Covid19
- Interventions
- Device: uEXPLORER/mCT
- Registration Number
- NCT04841707
- Lead Sponsor
- University of California, Davis
- Brief Summary
The primary objective is to measure the change between COVID-19 patients and normal subjects; the secondary objective is to measure the change in COVID-19 patients between baseline and 4-month follow up.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 13
Inclusion Criteria
- COVID-19 positive patients will have a previous positive COVID-19 test and radiographic findings, and/or a positive SARS-CoV-2 antibody test and be in early recovery.
- First PET/CT visit needs to be within 8 weeks of COVID-19 diagnosis.
- Ability to understand and willingness to sign an informed consent form.
- Ability to adhere to the study visit schedule and other protocol requirements.
- All persons ≥18 years of age.
Exclusion Criteria
- Pregnant or lactating women.
- Any condition that would prohibit the understanding or rendering of informed consent.
- Unable to lie supine for 1-hour imaging with PET.
- Prisoners.
- Any comorbidity that, in the opinion of the investigator, could compromise protocol objectives.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description COVID-19 patients uEXPLORER/mCT -
- Primary Outcome Measures
Name Time Method BAB permeability assessed 1 imaging visit up to 60 minutes Evaluating if there is a change in BAB permeability assessed by lung FDG K1 for patients with COVID 19
- Secondary Outcome Measures
Name Time Method 4 month follow-up PET/CT scan 1 imaging visit up to 60 minutes Evaluate the change in the scans between baseline scan and 4-month follow-up scan by assessing the pulmonary blood-air barrier permeability to glucose
Trial Locations
- Locations (1)
University of California, Davis
🇺🇸Sacramento, California, United States